Effects of telmisartan on insulin resistance in Japanese Type 2 diabetic patients

Internal Medicine

Volumn 49, Issue 17, 2010, Pages 1843-1847

  Watanabe, Masaki ^a   Inukai, Kouichi ^a   Sumita, Takashi ^a   Ikebukuro, Kaori ^a   Ito, Daisuke ^a   Kurihara, Susumu ^a   Ono, Hiraku ^a   Awata, Takuya ^a   Katayama, Shigehiro ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Insulin resistance; PPAR ; Telmisartan

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; CANDESARTAN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFONYLUREA DERIVATIVE; TELMISARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HOMEOSTASIS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; JAPANESE; LIPID BLOOD LEVEL; LIPID OXIDATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADIPONECTIN; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; FEMALE; HOMEOSTASIS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; JAPAN; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OXIDATIVE STRESS; PPAR GAMMA; TETRAZOLES;

EID: 77957895864     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3189     Document Type: Article

References (28)

1. Pi-Sunyer FX. The epidemiology of central fat distribution in relation to disease. Nutr Rev 62: S120-S126, 2004.
2. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286: H1597-H1602, 2004.
3. Morimoto S, Yano Y, Maki K, et al. Renal and vascular protective effects of telmisartan in patients with essential hypertension. Hypertens Res 29: 567-572, 2006.
4. Takai S, Kirimura K, Jin D, et al. Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 28: 593-600, 2005.
5. Ishimitsu T, Kobayashi T, Honda T, et al. Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 28: 351-359, 2005.
6. Ball SG. Benefits of blood pressure reduction in diabetic patients. J Hypertens 21: S31-S36, 2003.
7. Gillespie EL, White CM, Kardas M, Lindberg M, Coleman CI. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 28: 2261-2266, 2005.
8. Spiegelman BM, Heinrich R. Biological control through regulated transcriptional coactivators. Cell 119: 157-167, 2004.
9. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51: 2968-2974, 2002.
10. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARP-modulating activity. Hypertension 43: 1-10, 2004.
11. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blocker induces peroxisome proliferator-activated receptor-rractivity. Circulation 109: 2054-2057, 2004.
12. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferator-activated receptor o modulates angiotensin receptor blocking activity. Diabetes 54: 3442-3452, 2005.
13. Watanabe M, Inukai K, Katagiri H, Awata T, Oka Y, Katayama S. Regulation of PPARRRtranscriptional activity in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun 300: 429-436, 2003.
14. Tontonoz P, Hu RA, Graves AI, Budavari AI, Spiegelman BM. mPPARm2: tissue-specific regulator of an adipocyte enhancer. Gene & Dev 8: 1224-1234, 1994.
15. Kawamori R, Kadowaki T, Onji M, Seino Y, Akanuma Y. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diab Res Clin Pract 76: 229-235, 2007.
16. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23: 1792-1823, 2001.
17. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43: 48-56, 2004.
18. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663, 2003.
19. Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care 27: 41-46, 2004.
20. Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL. Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 43: 48-56, 2004.
21. Rueckschloss U, Galle J, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22: 1845-1851, 2002.
22. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004.
23. Syrbe U, Moebes A, Scholze J, Swidsinski A, Dörffel Y. Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension. Hypertens Res 30: 521-528, 2007.
24. Araki K, Masaki T, Katsuragi I, Tanaka K, Kakuma T, Yoshimatsu H. Telmisartan prevents obesity and increases the expression of uncoupling protein 1 in diet-induced obese mice. Hypertension 48: 51-57, 2006.
25. Sugimoto K, Qi NR, Kazdova L, Pravenec M, Ogihara T, Kurts TW. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis. Hypertension 47: 1-7, 2006.
26. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and anti-atherogenic consequences. Diabetes Care 28: 757-758, 2005.
27. Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome. Hypertens Res 30: 49-53, 2007.
28. Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 24: 146-153, 2007.